This study, sponsored by the University of Missouri-Columbia, aims to enhance the understanding of speech motor performance in patients with ALS and Parkinson's disease. The insights gained could lead to the development of more sensitive assessments for progressive speech loss, potentially improving the timing and effectiveness of speech therapies. The market for speech therapy and related interventions is significant, particularly as the prevalence of neurodegenerative disorders increases. The findings may position the sponsor as a leader in innovative assessment tools, attracting interest from pharmaceutical companies and healthcare providers focused on neurological conditions. Competitive implications include the potential for partnerships or licensing opportunities with organizations specializing in speech therapy technologies and interventions.